May 11, 2018
Video
Ahmad Tarhini, MD, PhD, director of the Melanoma and Skin Cancer Program and Immune-Oncology Research at the Cleveland Clinic Taussig Cancer Institute, discusses 3 recent trials that are changing the adjuvant treatment landscape of melanoma. The treatments presented in these trials have less toxicities overall and less impact on the quality of life, according to Tarhini.
April 22, 2015
Article
Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).